Neurotech International Ltd
Company Profile
Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUST: +61 394983132
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
18
Stocks News & Analysis
stocks
Is this ASX share a value trap or bargain?
stocks
Goldman Sachs Earnings: Valuations remain stretched
stocks
Major ASX listed miners overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,147.00 | 11.30 | -0.12% |
| CAC 40 | 8,112.02 | 146.92 | -1.78% |
| DAX 40 | 24,959.06 | 338.07 | -1.34% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,195.35 | 39.94 | -0.39% |
| HKSE | 26,500.77 | 63.13 | -0.24% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 52,931.11 | 652.46 | -1.22% |
| NZX 50 Index | 13,552.36 | 27.93 | -0.21% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,827.60 | 9.00 | -0.10% |
| SSE Composite Index | 4,099.67 | 14.33 | -0.35% |